Provectus Pharmaceuticals, Inc. (PVCT.OB) Moving Forward with Licensure of PV-10 for Metastatic Melanoma, Successfully Concludes End-of-Phase 2 FDA Meeting
Provectus Pharmaceuticals, Inc., a development-stage biopharma specialist creating innovative new therapies for the oncology (focused on melanoma) and dermatology markets, whose leading oncology agent, PV-10, is engineered to precisely target cancer cells without harming surrounding tissues while delimiting negative side effects, announced the holding of an end-of-Phase 2 meeting with the FDA regarding licensure endpoints and the potential clinical program scope of the Company’s metastatic melanoma formulation PV-10. Held at White Oak Campus, the FDA’s site in Silver Spring, MD, with the essential goal of creating consensus relevant to extant clinical data as to how to proceed, the meeting offered…
